A phase II evaluation of bacillus calmette-guerin plus megestrol acetate in patients with metastatic renal adenocarcinoma

The case is reported of a patient with pulmonary metastases from a renal adenocarcinoma who experienced subjective improvement and objective tumor regression on Bacillus Calmette‐Guerin (BCG) and megestrol acetate therapy. In a subsequent Phase II trial, no objective responses were noted among 15 pa...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Medical and pediatric oncology 1977, Vol.3 (3), p.237-242
Hauptverfasser:	Laucius, J. Frederick, Patel, Yogish A., Lusch, Charles J., Koons, Lawrence S., Bellet, Robert E., Mastrangelo, Michael J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adolescent Adult Aged Bacillus Calmette-Guerin BCG Vaccine - administration & dosage BCG Vaccine - therapeutic use Drug Evaluation Evaluation Studies as Topic Female Humans Immunoglobulins - analysis immunotherapy Injections, Intradermal Kidney Neoplasms - immunology Kidney Neoplasms - therapy Lung Neoplasms - immunology Lung Neoplasms - therapy Male Megestrol - administration & dosage Megestrol - therapeutic use megestrol acetate Middle Aged Neoplasm Metastasis renal adenocarcinoma Skin Tests
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The case is reported of a patient with pulmonary metastases from a renal adenocarcinoma who experienced subjective improvement and objective tumor regression on Bacillus Calmette‐Guerin (BCG) and megestrol acetate therapy. In a subsequent Phase II trial, no objective responses were noted among 15 patients treated with megestrol acetate (160 mg/day × 56 days) and BCG (five immunizing doses intradermally, every 2 weeks × 5). It is concluded that this treatment regimen is not clinically useful in patients with metastatic renal adenocarcinoma.
ISSN:	0098-1532 1096-911X
DOI:	10.1002/mpo.2950030304